The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations

Clinical Cancer Research

Volumn 9, Issue 4, 2003, Pages 1333-1337

  Mohamed, Anwar N ^a,b   Pemberton, Pamela ^a   Zonder, Jeffrey ^a   Schiffer, Charles A ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cytogenetics Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADULT; AGED; ARTICLE; BLAST CELL CRISIS; BONE MARROW TRANSPLANTATION; CHROMOSOME ABERRATION; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CLONOGENESIS; CYTOGENETICS; DISEASE COURSE; EOSINOPHILIA; FEMALE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REMISSION; STEM CELL TRANSPLANTATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0037388533     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Deininger, M. W. N., and Goldman, J. M. Chronic myeloid leukemia. Curr. Opin. Hematol., 5: 302-308, 1998.
2. Sawyers, C. L. Chronic myeloid leukemia. N. Engl. J. Med., 340: 1330-1340, 1999.
3. Rowley, J. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature (Lond.), 43: 290-293, 1973.
4. Faderl, S., Talpaz, M., Estrav, Z., O'Brien, S., Kuzrock, R., and Kantarjian, H. The biology of chronic myeloid leukemia. N. Engl. J. Med., 341: 167-172, 1999.
5. Deininger, M., Goldman, J., and Melo, J. The molecular biology of chronic myeloid leukemia. Blood, 96: 3343-3356, 2000.
6. Ben-Neriah, Y., Daley, G. Q., and Mes Masson, A-M. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science (Wash. DC), 233: 212-214, 1986.
7. Sawyers, C. L. Signal transduction pathways involved in BCR-ABL transformation. Baillieres Clin. Haematol., 10: 223-231, 1997.
8. Sacchi, S., Kantarjian, H., O'Brian, S., Cortes, J., Rios, M. B., Giles, F. J., Berab, M., Koller, C. A., Keating, M. J., and Talpaz, M. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer (Phila.), 86: 2632-2641, 1999.
9. Bernstein, R. Cytogenetics of chronic myelogenous leukemia. Semin. Hematol., 25: 20-34, 1988.
10. nd Ed. New York: Wiley-Liss, pp. 33-68, 1995.
11. Griffen, J. The biology of signal transduction inhibition: basic science to novel therapies. Semin. Oncol., 28: 3-8, 2001.
12. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., and Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 2: 561-566, 1996.
13. Deininger, M. W. N., Goldman, J. M., Lydon, N., and Melo, J. V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood, 90: 3691-3698, 1997.
14. Le Coutre, P., Mologni, L., Cleris, L., Marchesi, E., Buchdunger, E., Giardini, R., Formelli, F., and Gambacorti-Passerini, C. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer Inst., 91: 163-168, 1999.
15. Druker, B. J., and Lydon, N. B. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J. Clin. Investig., 105: 3-7, 2000.
16. Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 344: 1031-1037, 2001.
17. Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D., Reese, S. F., Ford, J., Capdeville, R., and Talpaz, M. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 344: 1038-1042, 2001.
18. ISCN. An International System for Human Cytogenetic Nomenclature. F. Mitelman, Ed. Basel: S Karger, 1995.
19. Kantarjian, H., and Talpaz, M. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias. Semin. Oncol., 28: 9-18, 2001.
20. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M., and Duker, B. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med., 346: 645-652, 2002.
21. Druker, B. J. for the IRIS Study Group. STI571 (Gleevec/Glivec, imatinib) vs interferon + cytarabine as initial therapy for patients with CML: results of a randomized study. Proc. Am. Soc. Clin. Oncol., 21: 1a, 2002.
22. Talpaz, M., Silver, R., Druker, B., Goldman, J., Gambacorti-Passerini, C., Guilhot, F., Schiffer, C., Fischeer, T., Deininger, M., Lennard, A., Hochhaus, A., Ottmann, O., Gratwohl, A., Baccarani, M., Stone, R., Tura, S., Mahon, F., Fernandes-reese, S., Gathmann, I., Capdeville, R., Kantarjian, H., and Sawyer, C. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood, 99: 1928-1937, 2002.
23. Sawyer, C., Hochhaus, A., Feldman, E., Goldman, J. M., Miller, C. B., Ottmann, O. G., Schiffer, C., Talpaz, M., Guilhot, F., Deininger, M., Fischer, T., O'Brien, S. G., Stone, R. M., Gambacorti-Passerini, C., Russell, N. H., Reiffers, J. J., Shea, T. C., Chapuis, B., Coutre, S., Tura, S., Morra, E., Larson, R. A., Saven, A., Peschel, C., Gratwohl, A., Mandelli, F., Ben-Am, M., Gathmann, I., Capdeville, R., Paquette, R. L., and Druker, B. J. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood, 99: 3530-3539, 2002.
24. O'Dwyer, M. E., Mauro, M. J., Kurilik, G., Mori, M., Balleisen, S., Olson, S., Magenis, E., Capdeville, R., and Druker, B. J. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood, 100: 1628-1633, 2002.
25. Le Coutre, P., Tassi, E., Varella-Garcia, M., Barni, R., Mologni, L., Cabrita, G., Marchesi, E., Supino, R., and Gambacort-Passerini, C. Introduction of resistance to the Abelson inhibitor STI571 in human leukemia cells through gene amplification. Blood, 95: 1758-1766, 2000.
26. Weisberg, E., and Griffin, J. D. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-ransformed hematopoietic cell lines. Blood, 95: 3498-3505, 2000.
27. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. Clinical resistance to STI-571 Cancer therapy caused by BCR-ABL gene mutation or amplification. Science (Wash. DC), 293: 876-880, 2001.
28. Shah, N., Nicoll, J., Gorre, M., Paquette, R., Ford, J., and Sawyers, C. Resistance to Gleevec; Sequence analysis reveals a spectrum of BCR/ABL kinase domain mutations in both acquired and de novoresistant cases of chronic myelogenous leukemia (CML). Blood, 99: 770a, 2001.
29. Mahon, F. X., Deininger, M. W., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. M., and Melo, J. V. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood, 96: 1070-1079, 2000.
30. Tipping, A., Mahon, F., Lagarde, V., Goldman, J., and Melo, J. Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells. Blood, 98: 3864-3867, 2001.
31. Vigneri, P., Wang, J. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat. Med., 7: 228-234, 2001.
32. Blagosklonny, M. V., Fojo, T., Bhalla, K. N., Kim, J. S., Trepel, J. B., Figg, W. D., Rivera, Y., and Neckers, L. M. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia (Baltimore), 15: 1537-1543, 2001.
33. Wadhwa, J., Szydlo, R., Apperly, J., Chase, A., Bua, M., Marin, D., Olavarria, E., Kanfer, E., and Goldman, J. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood. 99: 2304-2309, 2002.
34. Topaly, J., Zeller, W. J., and Fruehauf, S. Synergistic activity of the new Abl-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia (Baltimore), 15: 342-347, 2001.
35. Mow, B., Chandra, J., Svingen, P., Hallgren, C., Weinberg, E., Kottke, T., Narayanan, V., Litzow, M., Griffin, J., Sausville, Tefferi, A., and Kaufmann, S. Effects of the bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood, 99:664-671.